Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration of China for the "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2]. Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1]. - This new generation phosphate-potassium compound formulation aims to quickly correct phosphate deficiency while stabilizing cell membrane potential through potassium supplementation, thereby preventing risks associated with hypophosphatemia such as rhabdomyolysis and arrhythmias [1]. - The product is classified as a Category B item by the National Healthcare Security Administration, highlighting its high safety profile, rapid absorption, dual phosphate-potassium supplementation, and alignment with multiple clinical guidelines [1]. Group 2: Market Potential - According to data from Minai Network, the domestic sales of the "Compound Potassium Hydrogen Phosphate Injection" are projected to be 343 million yuan in 2023 and 413 million yuan in 2024 [1]. - The launch of this product enhances the company's portfolio in the nutritional supplement treatment sector, providing more treatment options for adults and children suffering from hypophosphatemia and those needing parenteral phosphate supplementation [2].
福森药业：“复合磷酸氢钾注射液”获批上市